Gene Mutations Linked With Environmental Factors in NSCLC

Share this content:
Oncogenic driver mutations in patients with non-small cell lung cancer may be associated with environmental factors.
Oncogenic driver mutations in patients with non-small cell lung cancer may be associated with environmental factors.

Oncogenic driver mutations in patients with non-small cell lung cancer (NSCLC) may be associated with smoking, body mass index (BMI), and other environmental factors, as well as with estrogen receptor β (ERβ) expression, according to a study published in the Journal of Clinical Oncology.1

Researchers led by Tomoya Kawaguchi, MD, PhD, of Osaka City University in Japan looked at 957 patients with newly diagnosed stages 1 to 3B NSCLC from July 2012 to December 2013 as part of a prospective, multicenter molecular epidemiology study.

They performed molecular analyses on 876 samples, examining for somatic mutations in 72 cancer-associated genes by targeted deep sequencing, ERβ expression through immunohistochemical staining, and infection with any of the 37  types of human papillomavirus (HPV) through a polymerase chain reaction-based microarray system. A questionnaire was used to obtain patient demographics and environmental factors.

They found that oncogenic driver mutations in P53 and KRAS had increased proportionally with smoking status, whereas mutations in EGFR and SMAD4 had decreased. KRAS mutations in smokers and SMAD4 mutations were observed more frequently in proportion to BMI.

RELATED: Four Quality Measures May Lengthen Survival in Patients With NSCLC

Furthermore, TP53 and NFE2L2 mutations were observed more frequently in advanced NSCLC stages. EGFR mutations were observed more frequently in women while TP53 mutations were observed more frequently in men, with mutations in both genes potentially associated with ERβ expression.

Reference

  1. Kawaguchi T, Koh Y, Ando M, et al. Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study [published online ahead of print May 9, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.64.2322.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs